| 产品描述: | CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity |
| 靶点: |
CDK9/cyclinT1:0.35 μM (IC50);CDK2/cyclinE:20 μM (IC50);cdk2/cyclin A:69 μM (IC50);Cdk4/cyclin D1:13.5 μM (IC50);CDK7/cyclin H:26 μM (IC50);Cdk1/cyclin B:44 μM (IC50);CDK |
| 体外研究: |
CAN508 reduces the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays.
CAN508 (20-40 μM; 72 hours) significantly reduces cell proliferation in a dose dependent manner in all three esophageal adenocarcinoma cell lines (SKGT4, OE33 and FLO-1 cells) with IC50s ranging from 34.99 to 91.09 μM.
CAN508 (40 μM; 72 hours) increases apoptosis in all three esophageal adenocarcinoma cells. |
| 体内研究: |
CAN508 (60 mg/kg; i.p.; daily for 10 days) has antitumor effects in esophageal adenocarcinoma xenografts. Animal Model: 4 weeks-old female nude mice (esophageal adenocarcinoma xenografts) Dosage: 60 mg/kg Administration: I.p.; daily for 10 days Result: Caused reduction of tumor growth starting from post-treatment day three with 50.83% reduction. |
| 参考文献: |
1. Krystof V, et al. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006;49(22):6500-6509.
2. Tong Z, et al. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017;8(17):28696-28710. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
4.583 ml |
22.913 ml |
45.825 ml |
| 5 mM |
0.917 ml |
4.583 ml |
9.165 ml |
| 10 mM |
0.458 ml |
2.291 ml |
4.583 ml |
| 50 mM |
0.092 ml |
0.458 ml |
0.917 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |